Lifetime Brands, Inc. reported net income of $10.6 million for the nine months ended September 30, 2026, a significant recovery from a $45.1 million net loss in the prior year period which was impacted by a $33.2 million goodwill impairment. The company also executed a debt refinancing during the third quarter, resulting in a $2.5 million loss on extinguishment of debt but restructuring its term loan and revolving credit facility.
Guardian Pharmacy Services reported Q3 2026 financial results with revenue of $371.1 million and net income of $19.1 million. The company raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing strong organic growth in residents served and successful integration of recent acquisitions.
Term
Q3 2026
“We are very pleased with our third-quarter performance, highlighted by strong resident and prescription growth. Absent the price reductions from the IRA, revenues would have been up high single digits compared to the third quarter of 2025, mostly driven by organic growth.”
Fred Burke, President and Chief Executive Officer
“With favorable industry fundamentals, a substantial runway for growth, and a liquid balance sheet, we believe Guardian is well positioned to generate durable growth and attractive long-term returns for shareholders.”
This document provides definitions for key financial and operational metrics used in Apollo Global Management's reporting, including Net Invested Assets, Net IRR, and Performance Fee-Eligible AUM. It details the components of Athene's retirement services segment and the methodology for calculating origination and perpetual capital. The filing serves as a glossary for understanding the firm's complex credit, equity, and retirement services business model.
For the nine months ended September 30, 2026, Kayne Anderson BDC reported total investment income of $172.0 million and net investment income of $86.6 million. The company experienced significant realized and unrealized losses totaling $51.5 million, resulting in a net increase in net assets from operations of $34.6 million, down from $71.7 million in the prior year period.
ICU Medical reported Q3 2026 revenue of $560.4 million, up from $537.0 million in the prior year, with GAAP net income of $26.8 million compared to a net loss in the same period last year. The company reaffirmed its full-year 2026 guidance, noting it expects results to land at the high end of its previously stated ranges.
Term
Q3 2026
“Third quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”
PAR Technology reported Q3 2026 revenues of $137.1 million, a 15% increase year-over-year, and narrowed its GAAP net loss to $9.0 million. The company also raised its full-year 2026 revenue guidance to a range of $532.5 million to $536.5 million, citing strong momentum in enterprise deployments and multi-product adoption.
Term
Q3 2026
“Our third quarter performance demonstrated the continued acceleration in growth and profitability we’ve been building toward. We exited the quarter with strong momentum across the business, supported by enterprise deployments, growing multi-product adoption, and a healthy pipeline that positions us well to finish the year strong and carry that progress into 2027.”
Savneet Singh, CEO
“Our operational discipline is allowing us to deliver improving profitability today while continuing to make the long-term investments needed to capture the significant AI and platform opportunity in front of us.”
Chimera Investment Corporation reported a net interest income of $71.2 million for the quarter ended September 30, 2026, up from $65.0 million in the prior year. However, the company experienced significant net unrealized losses on financial instruments at fair value totaling $391 million, contributing to a decrease in total stockholders' equity to $2.17 billion from $2.57 billion at year-end 2025.
Rigel Pharmaceuticals reported Q3 2026 total revenues of $80.9 million, driven by $72.3 million in net product sales and the commercial launch of VEPPANU. The company achieved net income of $13.2 million for the quarter and updated its full-year 2026 revenue outlook to a range of $290 million to $295 million.
Term
Q3 2026
“VEPPANU’s launch marks an exciting and transformational milestone for Rigel and we are very pleased with the initial uptake. In the first six weeks of launch we shipped VEPPANU to more than 100 patients and clinics and have already seen many refills.”
Raul Rodriguez, Rigel’s president and CEO
“Our priorities are to build on the VEPPANU launch and advance R289 in lower-risk MDS, with updated Phase 1b data to be presented at ASH in December. We believe VEPPANU and R289 have significant commercial potential to further transform Rigel and drive long-term shareholder value.”
For the nine months ended September 30, 2026, Park Hotels & Resorts reported total revenues of $1,904 million and net income of $47 million, a significant improvement from the $73 million net loss in the prior year period. The company successfully refinanced debt, issuing $700 million in mortgage debt to repay $1,400 million, while maintaining a portfolio of premium-branded hotels and resorts.
Alector reported Q3 2026 financial results, highlighting a cash position of $138.7 million and a runway extended into the second half of 2029 following a $100 million licensing deal with Genentech and a $75 million equity offering. The company is transitioning its pipeline to focus entirely on its Alector Brain Carrier (ABC) platform, with lead candidate AL137 expected to enter first-in-human dosing by April 2027.
Term
Q3 2026
“Since our last quarterly update, we exclusively licensed AL050 to Genentech, strengthened our balance sheet, and moved our wholly owned programs closer to the clinic. The Alector Brain Carrier is designed to address one of the central challenges in treating neurodegenerative disease: delivering enough drug to the brain.”
Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector
Enliven Therapeutics reported third quarter 2026 financial results and announced alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib. The company ended the quarter with $884.4 million in cash and marketable securities, providing a projected cash runway into 2030.
“This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial.”
Rick Fair, Chief Executive Officer of Enliven
“As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program.”
Definitive Healthcare Corp. filed its Q3 2026 Form 10-Q reporting 107,163,253 shares of Class A common stock outstanding as of November 2, 2026. The report highlights key operational risks including dependence on third-party data, the transition of its Chief Executive Officer, and potential transactions involving Advent International.
IonQ reported significant revenue growth to $173.8 million for the third quarter of 2026, though it continues to experience substantial operating losses and volatility from the change in fair value of warrant liabilities. The company's balance sheet remains complex with over $3.2 billion in goodwill and a total asset base of $7.85 billion following recent acquisitions.
IN8bio reported financial results for the third quarter of 2026, highlighting the appointment of Dr. Oxana Polyakova as SVP of R&D and progress in its gamma-delta T cell engager platform. The company remains on track to report initial in vivo preclinical data for its INB-619 program by the end of 2026.
Term
Q3 2026
“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform. It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”
Sarepta Therapeutics reported Q3 2026 financial results with net product revenues of $323.8 million, driven by its PMO franchise and ELEVIDYS. The company achieved positive cash flow and non-GAAP operating income of $22.9 million while preparing for Phase 3 development in its DM1 and FSHD programs.
Term
Q3 2026
“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.”
Michael Severino, M.D., chief executive officer, Sarepta
“This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve.”
Michael Severino, M.D., chief executive officer, Sarepta
AVITA Medical reported third quarter 2026 revenue of $26.1 million, a 53% increase year-over-year, driven by growth in its RECELL and Cohealyx products. The company raised its full-year 2026 revenue guidance to $92-$94 million and announced that improved liquidity has alleviated previous 'going concern' doubts. Additionally, the company met revenue milestones to access a final $10 million tranche of its credit facility with Perceptive Advisors.
Term
Q3 2026
“AVITA delivered another strong quarter, with revenue increasing 53% year over year and gross margin reaching 84%. RECELL continued to drive our growth, supported by increasing adoption of Cohealyx, while disciplined expense management contributed to a substantial improvement in cash use. Based on our year-to-date performance and continued commercial momentum, we are raising our full-year revenue guidance and remain on track to achieve cash flow breakeven in the fourth quarter.”
Cary Vance, President and Chief Executive Officer of AVITA Medical
“Reaching $85 million in trailing twelve-month revenue reflects the continued execution of our commercial strategy and satisfied the revenue condition required to draw down the remaining $10 million under our credit facility with Perceptive Advisors LLC. This additional, minimally dilutive capital strengthens our liquidity as we advance toward cash flow breakeven and cash generation in the fourth quarter.”
For the nine months ended September 30, 2026, Blend Labs reported total revenue of $97.6 million, an increase from $91.2 million in the prior year period, driven primarily by software platform growth. The company maintains a significant accumulated deficit of $1.4 billion and continues to operate as an emerging growth company with a focus on mortgage and consumer banking software.
Axcelis Technologies reported a 11.3% increase in quarterly revenue to $237.8 million for the period ended September 30, 2026, with net income rising to $37.8 million compared to $26.0 million in the prior year. Despite higher operating expenses, the company achieved a significant income tax benefit in the quarter, contributing to a diluted net income per share of $1.21.
Atlassian reported Q1 fiscal 2027 revenue of $1.77 billion, up 24% year-over-year, driven by 31% growth in Cloud revenue. The company also announced a leadership transition, with Eli Berkovitch appointed as Chief Accounting Officer to succeed Gene Liu.
Term
Q1 2027
“Q1 was a strong start to fiscal 2027, with RPO up 44% and Teamwork Collection customers up 7x year-over-year. Enterprise AI has hit an inflection point. Model power is table stakes. The advantage goes to platforms that bring people and AI agents together with shared context, deep collaboration, and confidence in the outcome. That’s what we’ve built. Our Teamwork Graph gives agents the context of how work actually gets done, and AMP brings them into teams as accountable teammates. We’ve never been better positioned, and we’re just getting started.”
Mike Cannon-Brookes, Atlassian’s CEO and Co‑Founder
“Subscription ARR grew 23% year-over-year and Cloud revenue grew 31% year-over-year, carrying forward our strong momentum across our strategic priorities of Enterprise, AI, and the System of Work. Customers are increasingly bringing teams, agents, and workflows onto the Atlassian platform as the Teamwork Graph provides unmatched context, enabling organizations to leverage the full potential of AI at enterprise scale. We paired that growth with continued operational discipline, expanding GAAP operating margin to 11% while generating $463 million in free cash flow, reflecting our commitment to durable, profitable growth.”
Tandem Diabetes Care reported sales of $283.7 million for the third quarter of 2026, a 14% increase year-over-year, while significantly narrowing its quarterly net loss to $7.1 million from $21.2 million in 2025. The company strengthened its balance sheet by issuing convertible senior notes due 2032, contributing to a total asset base of $1.16 billion as of September 30, 2026.
Serve Robotics reported Q3 2026 revenue of $2.8 million, a 313% year-over-year increase, driven by a shift toward higher-margin recurring revenue which now accounts for 69% of the mix. The company raised its full-year 2026 revenue guidance to $12 million and lowered its non-GAAP operating expense outlook to $150 million, citing strong cost discipline and robot demand.
“Serve is getting stronger on every front: demand for our robots is growing, the fleet costs less to operate, and we are opening new ways to generate revenue from what we have built. We are raising our full-year revenue guidance to $12 million. And, as we announced today, with the launch of Serve Physical AI Services, the technology behind our fleets is now available to other robot makers, a significant new opportunity for us.”
Dr. Ali Kashani, Serve’s Co-founder and CEO
“This quarter was about execution. Q3 revenue exceeded our expectations, and we drove operating expenses down while delivering more than 100 percentage points of sequential improvement in fleet margin. We believe the gains we made this quarter are structural, and they form the foundation for a long-term trend of improving unit economics.”
El Pollo Loco reported third quarter 2026 financial results with total revenue of $126.3 million and system-wide comparable restaurant sales growth of 5.0%. Net income for the quarter was $6.9 million, or $0.23 per diluted share, compared to $7.4 million in the prior year period. The company also announced it expects to open 25-30 new restaurants in 2027.
Term
Q3 2026
“We are thrilled to have delivered another strong quarter for El Pollo Loco. In addition to positive traffic growth, comparable sales were positive for the fourth straight quarter. Our strategy continues to deliver results, our marketing and innovation brought fresh energy to the brand, while our quality, value and improved service delivered a better experience for our guests.”
Liz Williams, Chief Executive Officer of El Pollo Loco Holdings, Inc.
Globus Medical reported Q3 2026 financial results with net sales of $763.7 million and GAAP net income of $141.2 million. Simultaneously, the company announced that its Board of Directors authorized a $500 million increase to its existing share repurchase program, bringing the total available for future buybacks to approximately $611 million.
“Third quarter revenue finished at $764 million, down slightly from the prior year quarter. U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation.”
Keith Pfeil, President and Chief Executive Officer
“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation.”
Mobia Medical reported Q3 2026 revenue of $15.6 million, a 73% year-over-year increase driven by broader adoption of its Vivistim System. The company also raised its full-year 2026 revenue guidance to a range of $57.0 million to $57.5 million, reflecting strong commercial execution and territory expansion.
Term
Q3 2026
“This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel.”
Richard Foust, President and Chief Executive Officer
“Additionally, we were pleased to announce the inclusion of paired VNS in the updated AHA Stroke guidelines for 2026, serving as validation of our evidence-based approach to stroke recovery and further recognition of how Vivistim® Paired VNS™ Therapy can redefine what is possible for stroke survivors.”
Richard Foust, President and Chief Executive Officer
AvePoint reported significant growth for the nine months ended September 30, 2026, with total revenue increasing to $372.8 million compared to $304.8 million in the prior year, driven primarily by SaaS revenue. Net income rose sharply to $60.8 million from $19.5 million, while the company aggressively repurchased $141.3 million of its common stock during the period.
Synaptics reported a net loss of $17.7 million for the quarter ended September 26, 2026, on revenue of $294.0 million. The company also announced a pending merger with ON Semiconductor Corporation (onsemi) for $123.00 per share in cash, which is expected to close in mid-2027.
Lyft reported record Q3 2026 financial results with Gross Bookings of $5.6 billion, up 17% year-over-year, and record Active Riders of 31.6 million. The company also announced the launch of its new membership program, Lyft Go, and its premium chauffeuring brand, Alcove, while continuing to expand autonomous vehicle partnerships with Waymo.
Term
Q3 2026
“Neither rain nor heat nor the gloom of night can slow Lyft’s business. Our customer obsession drove our best financial performance ever. And today we launched Lyft Go, the industry’s best membership program.”
David Risher, Lyft CEO
“Strong execution led to rides acceleration in North America and helped us to deliver record Active Riders, Rides, and Gross Bookings as we surpassed $1 billion in trailing twelve-month cash generation for the fifth straight quarter.”
Sana Biotechnology reported a net loss of $90.4 million for the nine months ended September 30, 2026, a significant improvement from the $185.3 million loss in the prior year period. The company achieved a net income of $20.4 million in the third quarter of 2026, primarily driven by a $63.4 million gain from the revaluation of research and development related success payments and contingent consideration.
Paycom Software reported total revenues of $543.8 million for the third quarter of 2026, representing a 10% increase year-over-year, while net income rose to $133.2 million. The company significantly increased its treasury stock through $1.42 billion in common stock repurchases during the first nine months of 2026 and took on $750 million in long-term debt.
Entravision Communications Corp reported a significant increase in net revenue to $651.2 million for the nine-month period ended September 30, 2026, compared to $313.2 million in the prior year. The company achieved a net income turnaround, reducing its accumulated deficit from $747.9 million at the end of 2025 to $696.8 million by September 30, 2026.